The HELIOS-B trial evaluated the efficacy of vutrisiran, a gene-silencing drug, in 655 patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). Patients were randomized to receive vutrisiran 25 mg administered by subcutaneous injection or placebo every 12 weeks for up to 36 months.
The primary endpoint, a composite of death from any cause and recurrent cardiovascular events (cardiovascular hospitalizations or urgent visits for heart failure), was 28% lower in the vutrisiran group compared to the placebo group. Vutrisiran also led to a 33% reduction in the primary endpoint in patients who received it as monotherapy and a 21% reduction in those also taking tafamidis, the first drug approved to treat this condition.
Additionally, there was a significant reduction in all-cause mortality in the overall population. Vutrisiran maintained functional capacity, health status, quality of life, and NT-proBNP levels, all measures of disease progression. The effects were particularly pronounced in patients with early-stage disease, highlighting the importance of early intervention.
The data support vutrisiran as a new standard of care for patients with ATTR-CM, as a first-line treatment for newly diagnosed patients and as a switch or add-on therapy for those progressing on tafamidis. Vutrisiran is the first drug in the gene-silencing class developed to treat ATTR-CM, providing a new mechanism of action and treatment option for this fatal disease.
To Another Language
from source content
www.medscape.com
Thông tin chi tiết chính được chắt lọc từ
by lúc www.medscape.com 09-09-2024
https://www.medscape.com/viewarticle/impressive-results-gene-silencer-attr-cardiomyopathy-2024a1000gbiYêu cầu sâu hơn